Hims & Hers lower after FDA warns of dosing errors with Ozempic

The Food and Drug Administration on Friday warned patients and doctors about dosing errors associated with compounded versions of Novo Nordisk’s weight loss and diabetes drugs, Reuters reports. The FDA said it has received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to patients incorrectly self-administering the compounded drug and health care providers miscalculating doses. Novo’s weight-loss drug, Wegovy, is available as single-dose pre-filled pens that deliver a preset dose for once weekly dosing. while its diabetes drug, Ozempic, is available as multiple-dose pre-filled pens for single-patient use, designed for once-weekly dosing, Reuters points out. Shares of Hims & Hers (HIMS), which offers an injectable weight loss drug with the same active ingredient as Novo’s Ozempic and Wegovy, are down 2% to $22.73 in morning trading.